Subcutaneous HER2+ Breast Cancer Treatment Trends

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

The panel discusses the evolving landscape of HER2-positive breast cancer treatment, focusing on subcutaneous administration of trastuzumab and pertuzumab. O’Shaughnessy highlights the patient-centric aspects, including shared decision-making, quality of life, and resource conservation. She references the FeDeriCa trial, which demonstrated comparable pathologic complete response rates between subcutaneous and intravenous administration. The PHranceSCa trial explored patient preferences, with the majority choosing the subcutaneous option. Time and motion studies revealed the subcutaneous route to be less resource-intensive, prompting a shift in some practices.

McArthur notes a predominant use of intravenous formulations during chemotherapy, transitioning to subcutaneous after completion. Rugo shares insights on challenges with insurance authorization for subcutaneous dosing. Despite the potential benefits, insurance denials and restrictions on biosimilars impact the adoption of subcutaneous administration. The discussion underscores the ongoing efforts to navigate insurance hurdles and optimize patient experience in HER2-positive breast cancer treatment.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.